Concepedia

Author

Nancy S. Shulman

Stanford University

Also Known As

N Shulman, N. S. Shulman, N. Shulman, N.S. Shulman, Nancy S Shulman, Nancy S. Shulman, Nancy Shulman, Nancy S. Shulman

85

Publications

3.2K

Citations

27

H-Index

49

Concepts

All Affiliations

Stanford UniversityLa Roche CollegeAbbVie (United States)Auckland Institute of StudiesRoche (Switzerland)
NS

About

Nancy S. Shulman is an author at Stanford University specializing in medicine, virology, and hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

25

1.5K

2

Hepatology

10

10

676

3

Immunology

10

10

480

4

Public Health

2

2

40

5

Epidemiology

1

1

11

Nancy S. Shulman

×

44

Publications

3K

Citations

27

H-Index

YearCitations

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Edward Gane, Stuart K. Roberts, Catherine AM Stedman,

The Lancet

2010

335

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Paul J. Pockros, K. Rajender Reddy, Parvez Mantry,

Gastroenterology

2016

277

Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients

Severine Margeridon‐Thermet, Nancy S. Shulman, Aijaz Ahmed,

The Journal of Infectious Diseases

2009

208

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee,

Hepatology

2018

176

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Jordan J. Feld, Christophe Moreno, Roger Trinh,

Journal of Hepatology

2015

160

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Jürgen K. Rockstroh, Karine Lacombe, Rolando M. Viani,

Clinical Infectious Diseases

2018

144

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial

Peter W. Hunt, Nancy S. Shulman, Timothy L. Hayes,

Blood

2013

133

Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 Infection

Thomas Campbell, Nancy S. Shulman, Steven C. Johnson,

Clinical Infectious Diseases

2005

120

Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry

Betsy C. Herold, S. Gerber, Brian J. Belval,

Journal of Virology

1996

108

Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine

Denise Lecossier, Nancy S. Shulman, Laurence Morand‐Joubert,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2004

104

Page 1